Charles River Laboratories International, Inc. $CRL Stock Position Lifted by Vanguard Group Inc.

Vanguard Group Inc. raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 0.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,839,743 shares of the medical research company’s stock after buying an additional 27,989 shares during the quarter. Vanguard Group Inc. owned 11.87% of Charles River Laboratories International worth $913,686,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in shares of Charles River Laboratories International by 14.5% in the third quarter. JPMorgan Chase & Co. now owns 317,179 shares of the medical research company’s stock worth $49,626,000 after acquiring an additional 40,073 shares during the last quarter. State of New Jersey Common Pension Fund D grew its stake in Charles River Laboratories International by 6.5% in the third quarter. State of New Jersey Common Pension Fund D now owns 17,922 shares of the medical research company’s stock valued at $2,804,000 after purchasing an additional 1,093 shares in the last quarter. Aberdeen Group plc grew its stake in Charles River Laboratories International by 58.9% in the third quarter. Aberdeen Group plc now owns 8,148 shares of the medical research company’s stock valued at $1,198,000 after purchasing an additional 3,021 shares in the last quarter. GF Fund Management CO. LTD. increased its position in Charles River Laboratories International by 10.3% in the 3rd quarter. GF Fund Management CO. LTD. now owns 1,348 shares of the medical research company’s stock worth $211,000 after purchasing an additional 126 shares during the last quarter. Finally, Assetmark Inc. raised its stake in shares of Charles River Laboratories International by 20.4% during the 3rd quarter. Assetmark Inc. now owns 37,143 shares of the medical research company’s stock worth $5,811,000 after purchasing an additional 6,301 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Morgan Stanley set a $185.00 price target on Charles River Laboratories International in a report on Monday, December 1st. Robert W. Baird set a $193.00 price objective on shares of Charles River Laboratories International in a research report on Thursday. Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price for the company in a research note on Monday, December 15th. Citigroup increased their price target on shares of Charles River Laboratories International from $200.00 to $265.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Barclays cut their price target on shares of Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $205.77.

Charles River Laboratories International Trading Up 3.1%

Shares of CRL stock opened at $169.26 on Monday. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $228.88. The company has a market cap of $8.33 billion, a PE ratio of -57.18, a price-to-earnings-growth ratio of 3.16 and a beta of 1.63. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. The business’s 50 day moving average is $200.37 and its two-hundred day moving average is $179.62.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. The business had revenue of $994.23 million during the quarter, compared to analysts’ expectations of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. Charles River Laboratories International’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the previous year, the company earned $2.66 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.